Paratek Pharmaceuticals
Developing transformative solutions for patients with infectious diseases.
HQ location
Boston, United States
Website
Launch date
Employees
Market cap
$132m
Enterprise value
$356m
Share price
€2.02 N4CN.F
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
* | $275m | Post IPO Debt | |
| Total Funding | 000k | ||
Omega Funds(exited)
Aisling Capital(exited)
Pacific Growth Equities(exited)
InterWest Partners(exited)
NEA(exited)
Novo Ventures(exited)
Gurnet Point Capital(exited)
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 36 % | (3 %) | 163 % | 178 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (650 %) | (589 %) | (678 %) | (170 %) | (34 %) | (30 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (706 %) | (656 %) | (778 %) | (222 %) | (49 %) | (42 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 476 % | 336 % | 239 % | 55 % | 25 % | 25 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Paratek Pharmaceuticals
Edit
ACQUISITION by Paratek Pharmaceuticals Oct 2014
ACQUISITION by Paratek Pharmaceuticals May 2025